Abstract Number: 0116 • ACR Convergence 2024
Assessment of Triple Antiphospholipid Antibody-positive Patients Based on Clinical and Laboratory Domains of 2023 ACR/EULAR Antiphospholipid Syndrome Classification Criteria
Background/Purpose: Triple aPL-positive (lupus anticoagulant test [LA], anticardiolipin antibody (aCL), and anti-β2 glycoprotein-I antibody [aβ2GPI]) patients are at higher risk to develop a severe clinical…Abstract Number: 0117 • ACR Convergence 2024
Validation of the 2023 American College of Rheumatology/European League Against Rheumatism Antiphospholipid Syndrome Classification Criteria in the Pediatric Population
Background/Purpose: Antiphospholipid syndrome (APS) is a systemic autoimmune disease characterized by arterial, venous or microvascular thrombosis, obstetric morbidity and/or non-thrombotic manifestations. The 2023 ACR/EULAR APS…Abstract Number: 0118 • ACR Convergence 2024
Performance of the 2023 ACR/EULAR Classification Criteria for Antiphospholipid Syndrome in a Mexican Cohort
Background/Purpose: The 2023 ACR/EULAR classification criteria (2023 AECC) for antiphospholipid syndrome (APS) were recently published. The new criteria require an entry criterion and employe a…Abstract Number: 1136 • ACR Convergence 2023
Challenges in Diagnosing VEXAS Syndrome: Delayed Diagnosis, Misdiagnosis, and Associations with Specific Gene Mutations
Background/Purpose: The newly described VEXAS syndrome is a very heterogenous disease with rheumatologic and hematologic manifestations, caused by somatic mutations affecting UBA1 gene, that still…Abstract Number: 1175 • ACR Convergence 2023
Inclusion of All Myositis Specific Autoantibodies or Other Rashes Leads to Better Sensitivity but Lower Specificity of 2017 EULAR/ACR Myositis Classification Criteria for Dermatomyositis
Background/Purpose: Idiopathic Inflammatory Myopathies (IIM), collectively known as myositis, are heterogeneous disorders characterized by muscle weakness and muscle inflammation. ACR/EULAR classification criterion for IIM was…Abstract Number: 1228 • ACR Convergence 2023
Validation of the PEDiatric Behçet’s Disease Classification Criteria (PEDBD): An International Consensus-based Approach
Background/Purpose: Behçet's disease (BD) is an autoinflammatory disease characterized by a variable vessel vasculitis. In the past, several criteria have been created for adult BD…Abstract Number: 1545 • ACR Convergence 2023
Validation of the 2022 American College of Rheumatology/European Alliance of Associations for Rheumatology Classification Criteria in Patients with ANCA-associated Vasculitis
Background/Purpose: The early diagnosis of ANCA-associated vasculitis (AAV) and treatment initiation may prevent progression to end organ damage, particularly renal disease. Based on the Vasculitis…Abstract Number: 1901 • ACR Convergence 2023
Which ASDAS-ESR Cut-offs for Disease Activity Correspond to ASDAS-CRP Cut-offs in Axial Spondyloarthritis? – Results from the EuroSpA Collaboration
Background/Purpose: When assessing disease activity in patients with axial spondyloarthritis (axSpA), the Ankylosing Spondylitis Disease Activity Score with C-reactive protein (ASDAS-CRP) is recommended over ASDAS…Abstract Number: 1943 • ACR Convergence 2023
IgG4-related Disease: 2010-2022 Case Review and Comparative Evaluation of Diagnostic Criteria
Background/Purpose: IgG4 immunoglobulin-related disease (IgG4-RD) is a rare, systemic immune-mediated fibro-inflammatory process with an unclear etiology and pathophysiology with the capacity of affecting multiple organs.…Abstract Number: 2264 • ACR Convergence 2023
Proposal for Defining Moderate and Severe Activity States in Systemic Lupus Erythematosus. Impact on Flares and Other Outcomes
Background/Purpose: In systemic lupus erythematosus (SLE), there is no definition of states of moderate and severe SLE activity. How these states may influence different disease…Abstract Number: 0108 • ACR Convergence 2023
Decoding Antiphospholipid Syndrome Laboratory Test Outcomes in a Large Multicenter Electronic Health Record Database
Background/Purpose: Electronic health record (EHR) data provide an inexpensive, information-rich tool to study rare diseases like antiphospholipid syndrome (APS). Many such studies rely on structured…Abstract Number: 2324 • ACR Convergence 2023
Leveraging ChatGPT for Real-World Systematic Lupus Erythematosus Data Curation from Electronic Health Records: A Feasibility Study
Background/Purpose: Epidemiologists, health services researchers, and health outcome investigators have begun utilizing real-world data (RWD) to gain valuable insights into disease patterns, treatment outcomes, and…Abstract Number: 0140 • ACR Convergence 2023
Extent of Recording of 2019 EULAR/ACR Classification Criteria for Systemic Lupus Erythematosus in a UK Healthcare Database
Background/Purpose: The 2019 EULAR/ACR Classification Criteria allow classification of patients with systemic lupus erythematosus (SLE) for research. They reflect updates in current understanding of SLE…Abstract Number: 2412 • ACR Convergence 2023
Evaluation of the Pretest Probability Score, Ultrasound and Biopsy on GCA Diagnose: Data from Real Clinical Practice
Background/Purpose: Giant cell arteritis (GCA) affects large and medium size arteries. Biopsy was considered the gold standard in the diagnosis1, but in the last years…Abstract Number: 0298 • ACR Convergence 2023
Accuracy of the 2017 European Alliance of Associations for Rheumatology (EULAR)/American College of Rheumatology (ACR) Classification Criteria and Myositis-Specific Autoantibodies-Based Classification Criteria for Classifying Patients with Idiopathic Inflammatory Myopathy
Background/Purpose: Limitations of the 2017 EULAR/ACR classification criteria have been suggested for classifying patients with idiopathic inflammatory myopathies (IIMs) and myositis-specific antibodies (MSAs). On this…
- « Previous Page
- 1
- 2
- 3
- 4
- …
- 11
- Next Page »